bullish
Moderna (MRNA US): Better-Than-Expected Q2 Result; Guidance Reiterated; $3B Share Buyback Announced
245 Views04 Aug 2022 19:53
SUMMARY
- Moderna Inc (MRNA US) reported strong Q2 results, with both revenue and EPS surpassing consensus. Profitability was negatively impacted by one-off inventory write-down charge.
- Management has reiterated advance purchase agreements for expected delivery of ~$21 billion in 2022. Assuming an endemic situation, Moderna’s commercial infrastructure is prepared for a 2023 commercial market.
- The Board of Directors has approved a new share repurchase program for $3 billion in August 2022, with no expiry. Moderna shares have gained 27% in last three months.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Moderna (MRNA US): Second Product Submission Is Not Big Enough Needle-Mover10 Jul 2023
- Reminder: Earnings Quality Short Candidates: Moderna, Sonos, Knowles, Juniper Tech11 Nov 2022
- Moderna (MRNA US): Q3 Result Misses Expectations; Guidance Slashed As COVID Vax Shipment Deferred04 Nov 2022
- Moderna (MRNA US): Better-Than-Expected Q2 Result; Guidance Reiterated; $3B Share Buyback Announced04 Aug 2022
- Moderna (MRNA US): Blowout Q1 Results; Maintained Guidance; Visibility Beyond COVID05 May 2022
- Moderna (MRNA US): To Cash in on Omicron Fear04 Dec 2021
- Autonomous Driving- Are We There Yet?20 Mar 2018
x